1
|
Obaha A, Novinec M. Regulation of Peptidase Activity beyond the Active Site in Human Health and Disease. Int J Mol Sci 2023; 24:17120. [PMID: 38069440 PMCID: PMC10707025 DOI: 10.3390/ijms242317120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2023] [Revised: 12/01/2023] [Accepted: 12/02/2023] [Indexed: 12/18/2023] Open
Abstract
This comprehensive review addresses the intricate and multifaceted regulation of peptidase activity in human health and disease, providing a comprehensive investigation that extends well beyond the boundaries of the active site. Our review focuses on multiple mechanisms and highlights the important role of exosites, allosteric sites, and processes involved in zymogen activation. These mechanisms play a central role in shaping the complex world of peptidase function and are promising potential targets for the development of innovative drugs and therapeutic interventions. The review also briefly discusses the influence of glycosaminoglycans and non-inhibitory binding proteins on enzyme activities. Understanding their role may be a crucial factor in the development of therapeutic strategies. By elucidating the intricate web of regulatory mechanisms that control peptidase activity, this review deepens our understanding in this field and provides a roadmap for various strategies to influence and modulate peptidase activity.
Collapse
Affiliation(s)
| | - Marko Novinec
- Faculty of Chemistry and Chemical Technology, Department of Chemistry and Biochemistry, University of Ljubljana, Večna pot 113, SI-1000 Ljubljana, Slovenia;
| |
Collapse
|
2
|
Chen LM, Chai KX. Exosome-Mediated Activation of the Prostasin-Matriptase Serine Protease Cascade in B Lymphoma Cells. Cancers (Basel) 2023; 15:3848. [PMID: 37568664 PMCID: PMC10417574 DOI: 10.3390/cancers15153848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2023] [Revised: 07/25/2023] [Accepted: 07/26/2023] [Indexed: 08/13/2023] Open
Abstract
Prostasin and matriptase are extracellular membrane serine proteases with opposing effects in solid epithelial tumors. Matriptase is an oncoprotein that promotes tumor initiation and progression, and prostasin is a tumor suppressor that reduces tumor invasion and metastasis. Previous studies have shown that a subgroup of Burkitt lymphoma have high levels of ectopic matriptase expression but no prostasin. Reducing the matriptase level via small interfering RNAs in B lymphoma cells impeded tumor xenograft growth in mice. Here, we report a novel approach to matriptase regulation in B cancer cells by prostasin via exosomes to initiate a prostasin-matriptase protease activation cascade. The activation and shedding of matriptase were monitored by measuring its quantity and trypsin-like serine protease activity in conditioned media. Sustained activation of the protease cascade in the cells was achieved by the stable expression of prostasin. The B cancer cells with prostasin expression presented phenotypes consistent with its tumor suppressor role, such as reduced growth and increased apoptosis. Prostasin exosomes could be developed as an agent to initiate the prostasin-matriptase cascade for treating B lymphoma with further studies in animal models.
Collapse
Affiliation(s)
- Li-Mei Chen
- Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA
| | - Karl X. Chai
- Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA
| |
Collapse
|
3
|
Liao AH, Chen YC, Chen CY, Chang SC, Chuang HC, Lin DL, Chiang CP, Wang CH, Wang JK. Mechanisms of ultrasound-microbubble cavitation for inducing the permeability of human skin. J Control Release 2022; 349:388-400. [PMID: 35787912 DOI: 10.1016/j.jconrel.2022.06.056] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 06/25/2022] [Accepted: 06/28/2022] [Indexed: 12/13/2022]
Abstract
We have previously reported that ultrasound (US)-mediated microbubble (MB) cavitation (US-MB) changed the permeability of the skin and significantly enhanced transdermal drug delivery (TDD) without changing the structure of the skin. In this study we found that US-MB enhanced TDD via disruption of epidermal cell-cell junctions and increased matriptase activity. Matriptase is a membrane-bound serine protease regulated by its inhibitor hepatocyte growth factor activator inhibitor-1 (HAI-1), and it is expressed in most epithelial tissues under physiologic conditions. Matriptase is expressed in mice after chronic exposure to UV radiation. This study found that US-MB can be used to monitor active matriptase, which rapidly formed the canonical 120-kDa matriptase-HAI-1 complex. These processes were observed in HaCaT human keratinocytes when matriptase activation was induced by US-MB. The results of immunoblot analysis indicated that the matriptase-HAI-1 complex can be detected from 10 min to 3 h after US-MB. Immunohistochemistry (IHC) of human skin revealed that US-MB rapidly increased the activated matriptase, which was observed in the basal layer, with this elevation lasting 3 h. After 3 h, the activated matriptase extended from the basal layer to the granular layer, and then gradually decayed from 6 to 12 h. Moreover, prostasin expression was observed in the epidermal granular layer to the spinous layer, and became more obvious in the granular layer after 3 h. Prostasin was also detected in the cytoplasm or on the cell membrane after 6 h. These results suggest that matriptase plays an important role in recovering from US-MB-induced epidermal cell-cell junction disruption within 6 h. US-MB is therefore a potentially effective method for noninvasive TDD in humans.
Collapse
Affiliation(s)
- Ai-Ho Liao
- Graduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei 10607, Taiwan; Department of Biomedical Engineering, National Defense Medical Center, Taipei 11490, Taiwan
| | - Yu-Chen Chen
- Graduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei 10607, Taiwan
| | - Chia-Yu Chen
- Graduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei 10607, Taiwan
| | - Shun-Cheng Chang
- Division of Plastic Surgery, Integrated Burn and Wound Care Center, Department of Surgery, Shuang-Ho Hospital, New Taipei City 235, Taiwan; Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
| | - Ho-Chiao Chuang
- Department of Mechanical Engineering, National Taipei University of Technology, Taipei 106344, Taiwan
| | - Dao-Lung Lin
- Spirit Scientific Co., Ltd. Taiwan Branch (Cayman), 12F-8, No. 99, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City 221416, Taiwan
| | - Chien-Ping Chiang
- Department of Dermatology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan; Department of Biochemistry, National Defense Medical Center, Taipei 11490, Taiwan
| | - Chih-Hung Wang
- Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 11490, Taiwan; Department of Otolaryngology-Head and Neck Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
| | - Jehng-Kang Wang
- Department of Biochemistry, National Defense Medical Center, Taipei 11490, Taiwan.
| |
Collapse
|
4
|
Lu DD, Gu Y, Li SWA, Barndt RJ, Huang SM, Wang JK, Su HC, Johnson MD, Lin CY. Targeted deletion of HAI-1 increases prostasin proteolysis but decreases matriptase proteolysis in human keratinocytes. Hum Cell 2021; 34:771-784. [PMID: 33486722 DOI: 10.1007/s13577-021-00488-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Accepted: 01/10/2021] [Indexed: 10/22/2022]
Abstract
Epidermal differentiation and barrier function require well-controlled matriptase and prostasin proteolysis, in which the Kunitz-type serine protease inhibitor HAI-1 represents the primary enzymatic inhibitor for both proteases. HAI-1, however, also functions as a chaperone-like protein necessary for normal matriptase synthesis and intracellular trafficking. Furthermore, other protease inhibitors, such as antithrombin and HAI-2, can also inhibit matriptase and prostasin in solution or in keratinocytes. It remains unclear, therefore, whether aberrant increases in matriptase and prostasin enzymatic activity would be the consequence of targeted deletion of HAI-1 and so subsequently contribute to the epidermal defects observed in HAI-1 knockout mice. The impact of HAI-1 deficiency on matriptase and prostasin proteolysis was, here, investigated in HaCaT human keratinocytes. Our results show that HAI-1 deficiency causes an increase in prostasin proteolysis via increased protein expression and zymogen activation. It remains unclear, however, whether HAI-1 deficiency increases "net" prostasin enzymatic activity because all of the activated prostasin was detected in complexes with HAI-2, suggesting that prostasin enzymatic activity is still under tight control in HAI-1-deficient keratinocytes. Matriptase proteolysis is, however, unexpectedly suppressed by HAI-1 deficiency, as manifested by decreases in zymogen activation, shedding of active matriptase, and matriptase-dependent prostasin zymogen activation. This suppressed proteolysis results mainly from the reduced ability of HAI-1-deficient HaCaT cells to activate matriptase and the rapid inhibition of nascent active matriptase by HAI-2 and other yet-to-be-identified protease inhibitors. Our study provides novel insights with opposite impacts by HAI-1 deficiency on matriptase versus prostasin proteolysis in keratinocytes.
Collapse
Affiliation(s)
- Dajun D Lu
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA
| | - Yayun Gu
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA
| | - Sheng-Wen A Li
- School of Medicine, National Defense Medical Center, Taipei 114, Taiwan
| | - Robert J Barndt
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA
| | - Shih-Ming Huang
- Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan
| | - Jehng-Kang Wang
- Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan
| | - Hui Chen Su
- Department of Pharmacy, Chi-Mei Medical Center, Tainan, Taiwan.
| | - Michael D Johnson
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA.
| | - Chen-Yong Lin
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, W412 Research Building 3970 Reservoir Road NW, Washington, DC, 20057, USA.
| |
Collapse
|
5
|
Zuo K, Qi Y, Yuan C, Jiang L, Xu P, Hu J, Huang M, Li J. Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors. Cancer Metastasis Rev 2020; 38:507-524. [PMID: 31471691 DOI: 10.1007/s10555-019-09802-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Matriptase is a type II transmembrane serine protease, which has been suggested to play critical roles in numerous pathways of biological developments. Matriptase is the activator of several oncogenic proteins, including urokinase-type plasminogen activator (uPA), hepatocyte growth factor (HGF) and protease-activated receptor 2 (PAR-2). The activations of these matriptase substrates subsequently lead to the generation of plasmin, matrix metalloproteases (MMPs), and the triggers for many other signaling pathways related to cancer proliferation and metastasis. Accordingly, matriptase is considered an emerging target for the treatments of cancer. Thus far, inhibitors of matriptase have been developed as potential anti-cancer agents, which include small-molecule inhibitors, peptide-based inhibitors, and monoclonal antibodies. This review covers established literature to summarize the chemical and biochemical aspects, especially the inhibitory mechanisms and structure-activity relationships (SARs) of matriptase inhibitors with the goal of proposing the strategies for their future developments in anti-cancer therapy.
Collapse
Affiliation(s)
- Ke Zuo
- College of Chemistry, Fuzhou University, Fuzhou, 350116, Fujian, People's Republic of China
| | - Yingying Qi
- College of Chemistry, Fuzhou University, Fuzhou, 350116, Fujian, People's Republic of China
| | - Cai Yuan
- College of Chemistry, Fuzhou University, Fuzhou, 350116, Fujian, People's Republic of China
| | - Longguang Jiang
- College of Chemistry, Fuzhou University, Fuzhou, 350116, Fujian, People's Republic of China
| | - Peng Xu
- Institute of Molecular and Cell Biology, A*STAR (Agency for Science, Technology and Research), 61 Biopolis Dr, 138673, Singapore, Singapore.
| | - Jianping Hu
- College of Pharmacy and Biological Engineering, Chengdu University, Chengdu, 610106, Sichuan, People's Republic of China.
| | - Mingdong Huang
- College of Chemistry, Fuzhou University, Fuzhou, 350116, Fujian, People's Republic of China.
| | - Jinyu Li
- College of Chemistry, Fuzhou University, Fuzhou, 350116, Fujian, People's Republic of China.
| |
Collapse
|
6
|
Ye F, Chen S, Liu X, Ye X, Wang K, Zeng Z, Su Y, Zhang X, Zhou H. 3-Cl-AHPC inhibits pro-HGF maturation by inducing matriptase/HAI-1 complex formation. J Cell Mol Med 2019; 23:155-166. [PMID: 30370662 PMCID: PMC6307790 DOI: 10.1111/jcmm.13900] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Accepted: 08/16/2018] [Indexed: 11/29/2022] Open
Abstract
Matriptase is an epithelia-specific membrane-anchored serine protease, and its dysregulation is highly related to the progression of a variety of cancers. Hepatocyte growth factor activator inhibitor-1 (HAI-1) inhibits matriptase activity through forming complex with activated matriptase. The balance of matriptase activation and matriptase/HAI-1 complex formation determines the intensity and duration of matriptase activity. 3-Cl-AHPC, 4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid, is an adamantly substituted retinoid-related molecule and a ligand of retinoic acid receptor γ (RARγ). 3-Cl-AHPC is of strong anti-cancer effect but with elusive mechanisms. In our current study, we show that 3-Cl-AHPC time- and dose- dependently induces matriptase/HAI-1 complex formation, leading to the suppression of activated matriptase in cancer cells and tissues. Furthermore, 3-Cl-AHPC promotes matriptase shedding but without increasing the activity of shed matriptase. Moreover, 3-Cl-AHPC inhibits matriptase-mediated cleavage of pro-HGF through matriptase/HAI-1 complex induction, resulting in the suppression of pro-HGF-stimulated signalling and cell scattering. Although 3-Cl-AHPC binds to RARγ, its induction of matriptase/HAI-1 complex is not RARγ dependent. Together, our data demonstrates that 3-Cl-AHPC down-regulates matriptase activity through induction of matriptase/HAI-1 complex formation in a RARγ-independent manner, providing a mechanism of 3-Cl-AHPC anti-cancer activity and a new strategy to inhibit abnormal matriptase activity via matriptase/HAI-1 complex induction using small molecules.
Collapse
Affiliation(s)
- Fang Ye
- School of Pharmaceutical SciencesFujian Provincial Key Laboratory of Innovative Drug Target ResearchXiamen UniversityXiamenFujianChina
| | - Shuang Chen
- School of Pharmaceutical SciencesFujian Provincial Key Laboratory of Innovative Drug Target ResearchXiamen UniversityXiamenFujianChina
| | - Xingxing Liu
- School of Pharmaceutical SciencesFujian Provincial Key Laboratory of Innovative Drug Target ResearchXiamen UniversityXiamenFujianChina
| | - Xiaohong Ye
- School of Pharmaceutical SciencesFujian Provincial Key Laboratory of Innovative Drug Target ResearchXiamen UniversityXiamenFujianChina
| | - Keqi Wang
- School of Pharmaceutical SciencesFujian Provincial Key Laboratory of Innovative Drug Target ResearchXiamen UniversityXiamenFujianChina
| | - Zhiping Zeng
- School of Pharmaceutical SciencesFujian Provincial Key Laboratory of Innovative Drug Target ResearchXiamen UniversityXiamenFujianChina
| | - Ying Su
- School of Pharmaceutical SciencesFujian Provincial Key Laboratory of Innovative Drug Target ResearchXiamen UniversityXiamenFujianChina
- Cancer CenterSanford Burnham Prebys Medical Discovery InstituteLa JollaCAUSA
| | - Xiao‐kun Zhang
- School of Pharmaceutical SciencesFujian Provincial Key Laboratory of Innovative Drug Target ResearchXiamen UniversityXiamenFujianChina
- Cancer CenterSanford Burnham Prebys Medical Discovery InstituteLa JollaCAUSA
| | - Hu Zhou
- School of Pharmaceutical SciencesFujian Provincial Key Laboratory of Innovative Drug Target ResearchXiamen UniversityXiamenFujianChina
| |
Collapse
|
7
|
Tamberg T, Hong Z, De Schepper D, Skovbjerg S, Dupont DM, Vitved L, Schar CR, Skjoedt K, Vogel LK, Jensen JK. Blocking the proteolytic activity of zymogen matriptase with antibody-based inhibitors. J Biol Chem 2018; 294:314-326. [PMID: 30409910 DOI: 10.1074/jbc.ra118.004126] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2018] [Revised: 11/04/2018] [Indexed: 11/06/2022] Open
Abstract
Matriptase is a member of the type-II transmembrane serine protease (TTSP) family and plays a crucial role in the development and maintenance of epithelial tissues. As all chymotrypsin-like serine proteases, matriptase is synthesized as a zymogen (proform), requiring a cleavage event for full activity. Recent studies suggest that the zymogen of matriptase possesses enough catalytic activity to not only facilitate autoactivation, but also carry out its in vivo functions, which include activating several proteolytic and signaling cascades. Inhibition of zymogen matriptase may therefore be a highly effective approach for limiting matriptase activity. To this end, here we sought to characterize the catalytic activity of human zymogen matriptase and to develop mAb inhibitors against this enzyme form. Using a mutated variant of matriptase in which the serine protease domain is locked in the zymogen conformation, we confirmed that the zymogen form of human matriptase has catalytic activity. Moreover, the crystal structure of the catalytic domain of zymogen matriptase was solved to 2.5 Å resolution to characterize specific antibody-based matriptase inhibitors and to further structure-based studies. Finally, we describe the first antibody-based competitive inhibitors that target both the zymogen and activated forms of matriptase. We propose that these antibodies provide a more efficient way to regulate matriptase activity by targeting the protease both before and after its activation and may be of value for both research and preclinical applications.
Collapse
Affiliation(s)
- Trine Tamberg
- Department of Molecular Biology and Genetics, Danish-Chinese Centre for Proteases and Cancer, Aarhus University, Gustav Wieds Vej 10C, Aarhus 8000, Denmark
| | - Zebin Hong
- Department of Molecular Biology and Genetics, Danish-Chinese Centre for Proteases and Cancer, Aarhus University, Gustav Wieds Vej 10C, Aarhus 8000, Denmark
| | - Daphné De Schepper
- Department of Molecular Biology and Genetics, Danish-Chinese Centre for Proteases and Cancer, Aarhus University, Gustav Wieds Vej 10C, Aarhus 8000, Denmark
| | - Signe Skovbjerg
- Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen 1165, Denmark
| | - Daniel M Dupont
- Department of Molecular Biology and Genetics, Danish-Chinese Centre for Proteases and Cancer, Aarhus University, Gustav Wieds Vej 10C, Aarhus 8000, Denmark
| | - Lars Vitved
- Department of Cancer and Inflammation, University of Southern Denmark, Odense 5230, Denmark
| | - Christine R Schar
- Department of Molecular Biology and Genetics, Danish-Chinese Centre for Proteases and Cancer, Aarhus University, Gustav Wieds Vej 10C, Aarhus 8000, Denmark
| | - Karsten Skjoedt
- Department of Cancer and Inflammation, University of Southern Denmark, Odense 5230, Denmark
| | - Lotte K Vogel
- Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen 1165, Denmark
| | - Jan K Jensen
- Department of Molecular Biology and Genetics, Danish-Chinese Centre for Proteases and Cancer, Aarhus University, Gustav Wieds Vej 10C, Aarhus 8000, Denmark.
| |
Collapse
|
8
|
Natural Endogenous Human Matriptase and Prostasin Undergo Zymogen Activation via Independent Mechanisms in an Uncoupled Manner. PLoS One 2016; 11:e0167894. [PMID: 27936035 PMCID: PMC5148038 DOI: 10.1371/journal.pone.0167894] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2016] [Accepted: 11/22/2016] [Indexed: 11/19/2022] Open
Abstract
The membrane-associated serine proteases matriptase and prostasin are believed to function in close partnership. Their zymogen activation has been reported to be tightly coupled, either as a matriptase-initiated proteolytic cascade or through a mutually dependent mechanism involving the formation of a reciprocal zymogen activation complex. Here we show that this putative relationship may not apply in the context of human matriptase and prostasin. First, the tightly coupled proteolytic cascade between matriptase and prostasin might not occur when modest matriptase activation is induced by sphingosine 1-phospahte in human mammary epithelial cells. Second, prostasin is not required and/or involved in matriptase autoactivation because matriptase can undergo zymogen activation in cells that do not endogenously express prostasin. Third, matriptase is not required for and/or involved in prostasin activation, since activated prostasin can be detected in cells expressing no endogenous matriptase. Finally, matriptase and prostasin both undergo zymogen activation through an apparently un-coupled mechanism in cells endogenously expressing both proteases, such as in Caco-2 cells. In these human enterocytes, matriptase is detected primarily in the zymogen form and prostasin predominantly as the activated form, either in complexes with protease inhibitors or as the free active form. The negligible levels of prostasin zymogen with high levels of matriptase zymogen suggests that the reciprocal zymogen activation complex is likely not the mechanism for matriptase zymogen activation. Furthermore, high level prostasin activation still occurs in Caco-2 variants with reduced or absent matriptase expression, indicating that matriptase is not required and/or involved in prostasin zymogen activation. Collectively, these data suggest that any functional relationship between natural endogenous human matriptase and prostasin does not occur at the level of zymogen activation.
Collapse
|
9
|
Chen YW, Yin S, Lai YJJ, Johnson MD, Lin CY. Plasminogen-Dependent Matriptase Activation Accelerates Plasmin Generation by Differentiating Primary Human Keratinocytes. J Invest Dermatol 2016; 136:1210-1218. [DOI: 10.1016/j.jid.2016.01.029] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2015] [Revised: 01/19/2016] [Accepted: 01/25/2016] [Indexed: 11/25/2022]
|
10
|
Dahlin JL, Nissink JWM, Francis S, Strasser JM, John K, Zhang Z, Walters MA. Post-HTS case report and structural alert: Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR. Bioorg Med Chem Lett 2015; 25:4740-4752. [PMID: 26318992 PMCID: PMC6002837 DOI: 10.1016/j.bmcl.2015.08.020] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2015] [Revised: 07/29/2015] [Accepted: 08/06/2015] [Indexed: 12/19/2022]
Abstract
Despite its wide use, not every high-throughput screen (HTS) yields chemical matter suitable for drug development campaigns, and seldom are 'go/no-go' decisions in drug discovery described in detail. This case report describes the follow-up of a 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one active from a cell-free HTS to identify small-molecule inhibitors of Rtt109-catalyzed histone acetylation. While this compound and structural analogs inhibited Rtt109-catalyzed histone acetylation in vitro, further work on this series was halted after several risk mitigation strategies were performed. Compounds with this chemotype had a poor structure-activity relationship, exhibited poor selectivity among other histone acetyltransferases, and tested positive in a β-lactamase counter-screen for chemical aggregates. Furthermore, ALARM NMR demonstrated compounds with this chemotype grossly perturbed the conformation of the La protein. In retrospect, this chemotype was flagged as a 'frequent hitter' in an analysis of a large corporate screening deck, yet similar compounds have been published as screening actives or chemical probes versus unrelated biological targets. This report-including the decision-making process behind the 'no-go' decision-should be informative for groups engaged in post-HTS triage and highlight the importance of considering physicochemical properties in early drug discovery.
Collapse
Affiliation(s)
- Jayme L Dahlin
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA; Medical Scientist Training Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
| | | | - Subhashree Francis
- Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, MN 55414, USA
| | - Jessica M Strasser
- Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, MN 55414, USA
| | - Kristen John
- Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, MN 55414, USA
| | - Zhiguo Zhang
- Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
| | - Michael A Walters
- Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, MN 55414, USA.
| |
Collapse
|
11
|
Lai YJJ, Chang HHD, Lai H, Xu Y, Shiao F, Huang N, Li L, Lee MS, Johnson MD, Wang JK, Lin CY. N-Glycan Branching Affects the Subcellular Distribution of and Inhibition of Matriptase by HAI-2/Placental Bikunin. PLoS One 2015; 10:e0132163. [PMID: 26171609 PMCID: PMC4501743 DOI: 10.1371/journal.pone.0132163] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2015] [Accepted: 06/10/2015] [Indexed: 12/14/2022] Open
Abstract
The gene product of SPINT 2, that encodes a transmembrane, Kunitz-type serine protease inhibitor independently designated as HAI-2 or placenta bikunin (PB), is involved in regulation of sodium absorption in human gastrointestinal track. Here, we show that SPINT 2 is expressed as two species of different size (30-40- versus 25-kDa) due to different N-glycans on Asn-57. The N-glycan on 25-kDa HAI-2 appears to be of the oligomannose type and that on 30-40-kDa HAI-2 to be of complex type with extensive terminal N-acetylglucosamine branching. The two different types of N-glycan differentially mask two epitopes on HAI-2 polypeptide, recognized by two different HAI-2 mAbs. The 30-40-kDa form may be mature HAI-2, and is primarily localized in vesicles/granules. The 25-kDa form is likely immature HAI-2, that remains in the endoplasmic reticulum (ER) in the perinuclear regions of mammary epithelial cells. The two different N-glycans could, therefore, represent different maturation stages of N-glycosylation with the 25-kDa likely a precursor of the 30-40-kDa HAI-2, with the ratio of their levels roughly similar among a variety of cells. In breast cancer cells, a significant amount of the 30-40-kDa HAI-2 can translocate to and inhibit matriptase on the cell surface, followed by shedding of the matriptase-HAI-2 complex. The 25-kDa HAI-2 appears to have also exited the ER/Golgi, being localized at the cytoplasmic face of the plasma membrane of breast cancer cells. While the 25-kDa HAI-2 was also detected at the extracellular face of plasma membrane at very low levels it appears to have no role in matriptase inhibition probably due to its paucity on the cell surface. Our study reveals that N-glycan branching regulates HAI-2 through different subcellular distribution and subsequently access to different target proteases.
Collapse
Affiliation(s)
- Ying-Jung J. Lai
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington DC, United States of America
| | - Hsiang-Hua D. Chang
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington DC, United States of America
- Department of Biochemistry, National Defense Medical Center, Taipei City, Taiwan
| | - Hongyu Lai
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington DC, United States of America
| | - Yuan Xu
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington DC, United States of America
| | - Frank Shiao
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington DC, United States of America
| | - Nanxi Huang
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington DC, United States of America
| | - Linpei Li
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington DC, United States of America
- Affiliated Hospital of Hunan Traditional Chinese Medicine Research Institute, Changsha, Hunan, China,s
| | - Ming-Shyue Lee
- Graduate Institute of Biochemistry and Molecular Biology, College of Medicine National Taiwan University, Taipei City, Taiwan
| | - Michael D. Johnson
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington DC, United States of America
| | - Jehng-Kang Wang
- Department of Biochemistry, National Defense Medical Center, Taipei City, Taiwan
- * E-mail: (CYL); (JKW)
| | - Chen-Yong Lin
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington DC, United States of America
- * E-mail: (CYL); (JKW)
| |
Collapse
|
12
|
Chang HHD, Xu Y, Lai H, Yang X, Tseng CC, Lai YJJ, Pan Y, Zhou E, Johnson MD, Wang JK, Lin CY. Differential subcellular localization renders HAI-2 a matriptase inhibitor in breast cancer cells but not in mammary epithelial cells. PLoS One 2015; 10:e0120489. [PMID: 25786220 PMCID: PMC4364774 DOI: 10.1371/journal.pone.0120489] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2014] [Accepted: 01/22/2015] [Indexed: 01/07/2023] Open
Abstract
The type 2 transmembrane serine protease matriptase is under tight control primarily by the actions of the integral membrane Kunitz-type serine protease inhibitor HAI-1. Growing evidence indicates that HAI-2 might also be involved in matriptase inhibition in some contexts. Here we showed that matriptase inhibition by HAI-2 depends on the subcellular localizations of HAI-2, and is observed in breast cancer cells but not in mammary epithelial cells. HAI-2 is co-expressed with matriptase in 21 out of 26 human epithelial and carcinoma cells examined. HAI-2 is also a potent matriptase inhibitor in solution, but in spite of this, HAI-2 inhibition of matriptase is not observed in all contexts where HAI-2 is expressed, unlike what is seen for HAI-1. Induction of matriptase zymogen activation in mammary epithelial cells results in the formation of matriptase-HAI-1 complexes, but matriptase-HAI-2 complexes are not observed. In breast cancer cells, however, in addition to the appearance of matriptase-HAI-1 complex, three different matriptase-HAI-2 complexes, are formed following the induction of matriptase activation. Immunofluorescent staining reveals that activated matriptase is focused at the cell-cell junctions upon the induction of matriptase zymogen activation in both mammary epithelial cells and breast cancer cells. HAI-2, in contrast, remains localized in vesicle/granule-like structures during matriptase zymogen activation in human mammary epithelial cells. In breast cancer cells, however, a proportion of the HAI-2 reaches the cell surface where it can gain access to and inhibit active matriptase. Collectively, these data suggest that matriptase inhibition by HAI-2 requires the translocation of HAI-2 to the cell surface, a process which is observed in some breast cancer cells but not in mammary epithelial cells.
Collapse
Affiliation(s)
- Hsiang-Hua D. Chang
- Lombardi Comprehensive Cancer Center, Department of Oncology Georgetown University Washington, DC, 20057, United States of America
- Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan, ROC
| | - Yuan Xu
- Lombardi Comprehensive Cancer Center, Department of Oncology Georgetown University Washington, DC, 20057, United States of America
| | - Hongyu Lai
- Lombardi Comprehensive Cancer Center, Department of Oncology Georgetown University Washington, DC, 20057, United States of America
| | - Xiaoyu Yang
- Lombardi Comprehensive Cancer Center, Department of Oncology Georgetown University Washington, DC, 20057, United States of America
| | - Chun-Che Tseng
- Lombardi Comprehensive Cancer Center, Department of Oncology Georgetown University Washington, DC, 20057, United States of America
- Department of Biology, Carleton College, Northfield, MN, 55057, United States of America
| | - Ying-Jung J. Lai
- Lombardi Comprehensive Cancer Center, Department of Oncology Georgetown University Washington, DC, 20057, United States of America
| | - Yu Pan
- Lombardi Comprehensive Cancer Center, Department of Oncology Georgetown University Washington, DC, 20057, United States of America
| | - Emily Zhou
- Thomas Jefferson High School for Science and Technology, Alexandria, VA, 22046, United States of America
| | - Michael D. Johnson
- Lombardi Comprehensive Cancer Center, Department of Oncology Georgetown University Washington, DC, 20057, United States of America
| | - Jehng-Kang Wang
- Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan, ROC
- * E-mail:
| | - Chen-Yong Lin
- Lombardi Comprehensive Cancer Center, Department of Oncology Georgetown University Washington, DC, 20057, United States of America
| |
Collapse
|
13
|
Wang JK, Teng IJ, Lo TJ, Moore S, Yeo YH, Teng YC, Kaul M, Chen CC, Zuo AH, Chou FP, Yang X, Tseng IC, Johnson MD, Lin CY. Matriptase autoactivation is tightly regulated by the cellular chemical environments. PLoS One 2014; 9:e93899. [PMID: 24705933 PMCID: PMC3976350 DOI: 10.1371/journal.pone.0093899] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2014] [Accepted: 03/07/2014] [Indexed: 12/17/2022] Open
Abstract
The ability of cells to rapidly detect and react to alterations in their chemical environment, such as pH, ionic strength and redox potential, is essential for cell function and survival. We present here evidence that cells can respond to such environmental alterations by rapid induction of matriptase autoactivation. Specifically, we show that matriptase autoactivation can occur spontaneously at physiological pH, and is significantly enhanced by acidic pH, both in a cell-free system and in living cells. The acid-accelerated autoactivation can be attenuated by chloride, a property that may be part of a safety mechanism to prevent unregulated matriptase autoactivation. Additionally, the thio-redox balance of the environment also modulates matriptase autoactivation. Using the cell-free system, we show that matriptase autoactivation is suppressed by cytosolic reductive factors, with this cytosolic suppression being reverted by the addition of oxidizing agents. In living cells, we observed rapid induction of matriptase autoactivation upon exposure to toxic metal ions known to induce oxidative stress, including CoCl2 and CdCl2. The metal-induced matriptase autoactivation is suppressed by N-acetylcysteine, supporting the putative role of altered cellular redox state in metal induced matriptase autoactivation. Furthermore, matriptase knockdown rendered cells more susceptible to CdCl2-induced cell death compared to control cells. This observation implies that the metal-induced matriptase autoactivation confers cells with the ability to survive exposure to toxic metals and/or oxidative stress. Our results suggest that matriptase can act as a cellular sensor of the chemical environment of the cell that allows the cell to respond to and protect itself from changes in the chemical milieu.
Collapse
Affiliation(s)
- Jehng-Kang Wang
- Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan
| | - I-Jou Teng
- Department of Medicine, National Defense Medical Center, Taipei, Taiwan
| | - Ting-Jen Lo
- Department of Medicine, National Defense Medical Center, Taipei, Taiwan
| | - Sean Moore
- Geenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States of America
| | - Yee Hui Yeo
- Department of Medicine, National Defense Medical Center, Taipei, Taiwan
| | - Yun-Chung Teng
- Department of Biomedical Engineering National Yang Ming University, Taipei, Taiwan
| | - Malvika Kaul
- Department of Pharmacology, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey, United States of America
| | - Chiann-Chyi Chen
- Department of Pharmacology, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey, United States of America
| | - Annie Hong Zuo
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, United States of America
| | - Fen-Pai Chou
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, United States of America
| | - Xiaoyu Yang
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, United States of America
| | - I-Chu Tseng
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, United States of America
| | - Michael D. Johnson
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, United States of America
| | - Chen-Yong Lin
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, United States of America
- * E-mail:
| |
Collapse
|
14
|
Gray K, Elghadban S, Thongyoo P, Owen KA, Szabo R, Bugge TH, Tate EW, Leatherbarrow RJ, Ellis V. Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II. Thromb Haemost 2014; 112:402-11. [PMID: 24696092 DOI: 10.1160/th13-11-0895] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2013] [Accepted: 03/10/2014] [Indexed: 12/14/2022]
Abstract
Matriptase is a type-II transmembrane serine protease involved in epithelial homeostasis in both health and disease, and is implicated in the development and progression of a variety of cancers. Matriptase mediates its biological effects both via as yet undefined substrates and pathways, and also by proteolytic cleavage of a variety of well-defined protein substrates, several of which it shares with the closely-related protease hepsin. Development of targeted therapeutic strategies will require discrimination between these proteases. Here we have investigated cyclic microproteins of the squash Momordica cochinchinensis trypsin-inhibitor family (generated by total chemical synthesis) and found MCoTI-II to be a high-affinity (Ki 9 nM) and highly selective (> 1,000-fold) inhibitor of matriptase. MCoTI-II efficiently inhibited the proteolytic activation of pro-hepatocyte growth factor (HGF) by matriptase but not by hepsin, in both purified and cell-based systems, and inhibited HGF-dependent cell scattering. MCoTI-II also selectively inhibited the invasion of matriptase-expressing prostate cancer cells. Using a model of epithelial cell tight junction assembly, we also found that MCoTI-II could effectively inhibit the re-establishment of tight junctions and epithelial barrier function in MDCK-I cells after disruption, consistent with the role of matriptase in regulating epithelial integrity. Surprisingly, MCoTI-II was unable to inhibit matriptase-dependent proteolytic activation of prostasin, a GPI-anchored serine protease also implicated in epithelial homeostasis. These observations suggest that the unusually high selectivity afforded by MCoTI-II and its biological effectiveness might represent a useful starting point for the development of therapeutic inhibitors, and further highlight the role of matriptase in epithelial maintenance.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - V Ellis
- Vincent Ellis, PhD, School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK, Tel.: +44 1603 592570, E-mail:
| |
Collapse
|
15
|
Chu LL, Xu Y, Yang JR, Hu YA, Chang HH, Lai HY, Tseng CC, Wang HY, Johnson MD, Wang JK, Lin CY. Human cancer cells retain modest levels of enzymatically active matriptase only in extracellular milieu following induction of zymogen activation. PLoS One 2014; 9:e92244. [PMID: 24663123 PMCID: PMC3963879 DOI: 10.1371/journal.pone.0092244] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2014] [Accepted: 02/09/2014] [Indexed: 11/18/2022] Open
Abstract
The type 2 transmembrane serine protease matriptase is broadly expressed in human carcinomas and hematological cancers. The proteolytic activity of matriptase is a potential target of drugs and imaging probes. We assessed the fate of active matriptase following the induction of matriptase zymogen activation. Exposing eight human carcinoma cells to pH 6.0 buffer induced robust matriptase zymogen activation followed by rapid inhibition of the nascent active matriptase by hepatocyte growth factor activator inhibitor (HAI)-1. Consequently, no enzymatically active matriptase was detected in these cells. Some active matriptase is, however, rapidly shed to the extracellular milieu by these carcinoma cells. The lack of cell-associated active matriptase and the shedding of active matriptase were also observed in two hematological cancer lines. Matriptase shedding is correlated closely with the induction of matriptase activation, suggesting that matriptase activation and shedding are kinetically coupled. The coupling allows a proportion of active matriptase to survive HAI-1 inhibition by rapid shedding from cell surface. Our study suggests that cellular free, active matriptase is scarce and might not be an effective target for in vivo imaging and drug development.
Collapse
Affiliation(s)
- Li-Ling Chu
- Department of Pharmacy, Chi-Mei Medical Center, Tainan, Taiwan
| | - Yuan Xu
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, D.C., United States of America
| | - Jie-Ru Yang
- Department of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC
| | - Yi-An Hu
- Department of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC
| | - Hsiang-Hua Chang
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, D.C., United States of America
- Department of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC
| | - Hong-Yu Lai
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, D.C., United States of America
| | - Chun-Che Tseng
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, D.C., United States of America
- Department of Biology, Carleton College, Northfield, Minnesota, United States of America
| | - Hue-Yu Wang
- Department of Pharmacy, Chi-Mei Medical Center, Tainan, Taiwan
| | - Michael D. Johnson
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, D.C., United States of America
| | - Jehng-Kang Wang
- Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan, ROC
- * E-mail: (C-YL); (J-KW)
| | - Chen-Yong Lin
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, D.C., United States of America
- * E-mail: (C-YL); (J-KW)
| |
Collapse
|